[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Lab Reports
April 4, 2007

Dengue Drug Screen

JAMA. 2007;297(13):1423. doi:10.1001/jama.297.13.1423-b

A newly developed screening technology may be useful for identifying potential targets for drugs against dengue fever, an infectious disease that lacks effective prevention or treatment countermeasures (Chu JJ and Yang PL. Proc Natl Acad Sci U S A. 2007;104:3520-3525).

Using this microscopy-based immunofluorescence technology, investigators at Harvard Medical School, in Boston, discovered that inhibitors of the c-Src protein kinase hinder the mosquito-borne flavivirus that causes dengue fever. Further analysis revealed that the anticancer drug dasatinib, a c-Src protein kinase inhibitor, prevents the assembly of dengue virions and may therefore be an effective therapy.

First Page Preview View Large
First page PDF preview
First page PDF preview